Tarsus Pharmaceuticals (TARS) Net Income towards Common Stockholders (2019 - 2026)

Tarsus Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 72.33% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$148.9 million (down 44.76% YoY), while the FY2025 annual figure was -$66.4 million, up 42.52% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$6.9 million, down from -$5.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$5.5 million in Q2 2022, with the low at -$123.7 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is -$23.3 million (2023), against an average of -$28.5 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 474.12% in 2023, then soared 75.54% in 2025.
• Tarsus Pharmaceuticals' Net Income towards Common Stockholders stood at -$13.6 million in 2022, then sank by 210.57% to -$42.3 million in 2023, then surged by 45.45% to -$23.1 million in 2024, then jumped by 75.54% to -$5.6 million in 2025, then slipped by 22.68% to -$6.9 million in 2026.
• Business Quant data shows TARS's Net Income towards Common Stockholders at -$6.9 million in Q1 2026, -$5.6 million in Q4 2025, and -$12.7 million in Q3 2025.